Pharmaceutical Executive
Pharmaceutical Executive Daily: FDA Approves Simtriyo
July 27 · 3 min · 2.9 MB
0:00-3:02
Streams straight from the publisher. podnod never proxies or re-hosts episode audio.
In today's Pharmaceutical Executive Daily, FDA approves Otsuka's Simtriyo as the first NDSRI treatment for ADHD, argenx agrees to acquire Forte Biosciences for approximately $2.2 billion, and an AbbVie neuroscience researcher discusses the shift from symptom management to disease modification in Parkinson's research.
No links were found in this episode’s notes.